TG Therapeutics gets FDA-issued breakthrough treatment in new drug umbralisib (TGR-1202)
-
Last Update: 2020-06-10
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
MZL, which begins to grow in the edge region of lymphatic tissue, is an inert lymphoma that progresses and spreads slowlyMZL is the third most common B-cell non-Hodgkin lymphoma (non-Hodgkin lymphoma), which accounts for about 8% of the NHL totalMZL adds about 7,500 new cases per yeartoday, Bio
Pharmaceutical(http://, a company focused on developing innovative treatments for B-cell-related diseases, announced http://
todaythat it has been recognized by theFDA(http://for itsnew drug(http://Umbralisib will be used to treat patients with marginal area lymphoma (marginal zone lymphoma, MZL) who had received at least one anti-CD20 antibody therapy beforeThere are currently no approved treatments specifically for MZLabout umbralisib orally available umbralisib, a new generation of phosphatidyl inositol 3-kinase (PI3K) subtype of high-efficiency specific inhibitors that selectively inhibit PI3K-pyrion at the namol level PI3K-slug is thought to play an important role in the proliferation and survival of B lymphocytes Umbralisib demonstrated the powerful activity of treating malignant blood cancers in preclinical studies this breakthrough treatment was awarded based on the interim results of the Phase 2b Clinical Trial (http:// called UNITY-NHL The ongoing trial included the use of umbralisib as a single-drug therapy to treat MZL patients The top line results of the trial are expected to be released in mid-2019
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
